Dariusz Pytel to Protein-Tyrosine Kinases
This is a "connection" page, showing publications Dariusz Pytel has written about Protein-Tyrosine Kinases.
Connection Strength
0.878
-
Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem. 2009 Jan; 9(1):66-76.
Score: 0.319
-
Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. Comp Biochem Physiol C Toxicol Pharmacol. 2006 Sep; 144(1):85-92.
Score: 0.268
-
[The role of oncogenic tyrosine kinases in the cellular response to anticancer therapy]. Postepy Hig Med Dosw (Online). 2007 Dec 14; 61:819-27.
Score: 0.074
-
Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells. Z Naturforsch C J Biosci. 2006 Nov-Dec; 61(11-12):896-902.
Score: 0.069
-
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutat Res. 2006 Jan 31; 603(1):74-82.
Score: 0.065
-
[Tyrosine kinases. New target of anticancer therapy]. Postepy Biochem. 2005; 51(3):251-60.
Score: 0.060
-
BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res. 2011 Feb 01; 71(3):842-51.
Score: 0.023